{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:10:27Z","timestamp":1789564227355,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s12185-020-03031-4","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T10:02:52Z","timestamp":1605002572000},"page":"430-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Meropenem versus piperacillin\/tazobactam for febrile neutropenia in pediatric patients: efficacy of piperacillin\/tazobactam as a 1-h drip infusion four times a day"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3937-0856","authenticated-orcid":false,"given":"Ryoji","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirozumi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koya","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"key":"3031_CR1","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1046\/j.1365-2141.1997.4453255.x","volume":"99","author":"I Hann","year":"1997","unstructured":"Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol. 1997;99:580\u20138.","journal-title":"Br J Haematol."},{"key":"3031_CR2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/clinids\/13.3.397","volume":"13","author":"C Viscoli","year":"1991","unstructured":"Viscoli C, Moroni C, Boni L, Bruzzi P, Comelli A, Dini G, et al. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis. 1991;13:397\u2013404.","journal-title":"Rev Infect Dis"},{"key":"3031_CR3","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1200\/JCO.2016.71.7017","volume":"35","author":"T Lehrnbecher","year":"2017","unstructured":"Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol. 2017;35:2082\u201394.","journal-title":"J Clin Oncol"},{"key":"3031_CR4","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Infectious Diseases Society of America, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52:e56-93.","journal-title":"Clin Infect Dis."},{"key":"3031_CR5","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.7314\/APJCP.2014.15.11.4549","volume":"15","author":"G Sezgin","year":"2014","unstructured":"Sezgin G, Acipayam C, Ozkan A, Bayram I, Tanyeli A. Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients. Asian Pac J Cancer Prev. 2014;15:4549\u201353.","journal-title":"Asian Pac J Cancer Prev"},{"key":"3031_CR6","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/pbc.21692","volume":"51","author":"T Sato","year":"2008","unstructured":"Sato T, Kobayashi R, Yasuda K, Kaneda M, Iguchi A, Kobayashi K. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. Pediatr Blood Cancer. 2008;51:774\u20137.","journal-title":"Pediatr Blood Cancer"},{"key":"3031_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/MPH.0b013e31819daf4a","volume":"31","author":"R Kobayashi","year":"2009","unstructured":"Kobayashi R, Sato T, Nakajima M, Kaneda M, Iguchi A. Piperacillin\/tazobactam plus ceftazidime versus sulbactam\/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients. J Pediatr Hematol Oncol. 2009;31:270\u20133.","journal-title":"J Pediatr Hematol Oncol"},{"key":"3031_CR8","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/pbc.25148","volume":"61","author":"T Sarashina","year":"2014","unstructured":"Sarashina T, Kobayashi R, Yoshida M, Toriumi N, Suzuki D, Sano H, et al. A randomized trial of cefozopran versus cefepime as empirical antibiotic treatment of febrile neutropenia in pediatric cancer patients. Pediatr Blood Cancer. 2014;61:1992\u20135.","journal-title":"Pediatr Blood Cancer"},{"key":"3031_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/pbc.25178","volume":"62","author":"H Sano","year":"2015","unstructured":"Sano H, Kobayashi R, Suzuki D, Kishimoo K, Yasuda K, Kobayashi K. Comparison of Piperacillin Tazobactam and cefepime monotherapy as an empiric therapy for febrile neutropenia in children with hematological and malignant disorders: a prospective randomized study. Pediatr Blood Cancer. 2015;62:356\u20138.","journal-title":"Pediatr Blood Cancer"},{"key":"3031_CR10","doi-asserted-by":"publisher","first-page":"e26360","DOI":"10.1002\/pbc.26360","volume":"64","author":"H Sano","year":"2017","unstructured":"Sano H, Kobayashi R, Suzuki D, Hori D, Kishimoto K, Kobayashi K. A prospective randomized trial comparing piperacillin\/tazobactam with meropenem as empiric antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders. Pediatr Blood Cancer. 2017;64:e26360.","journal-title":"Pediatr Blood Cancer"},{"key":"3031_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3031_CR12","first-page":"S23","volume":"66","author":"C Viscoli","year":"2009","unstructured":"Viscoli C, Moroni C, Boni L, Bruzzi P, Comelli A, Dini G, et al. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm. 2009;66:S23-30.","journal-title":"Am J Health Syst Pharm"},{"key":"3031_CR13","first-page":"283","volume":"71","author":"F Sol\u00f3rzano-Santos","year":"2019","unstructured":"Sol\u00f3rzano-Santos F, Quezada-Herrera A, Fuentes-Pacheco Y, Rodr\u00edguez-Coello G, Aguirre-Morales CE, Izelo-Flores D, et al. Piperacillin\/tazobactam in continuous infusion versus intermittent infusion in children with febrile neutropenia. Rev Invest Clin. 2019;71:283\u201390.","journal-title":"Rev Invest Clin"},{"key":"3031_CR14","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1093\/jac\/dkz248","volume":"74","author":"N Benech","year":"2019","unstructured":"Benech N, Dumitrescu O, Conrad A, Balsat M, Paubelle E, Ducastelle-Lepretre S, Lyon HEMINF Study Group, et al. Parameters influencing the pharmacokinetics\/pharmacodynamics of piperacillin\/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study. J Antimicrob Chemother. 2019;74:2676\u201380.","journal-title":"J Antimicrob Chemother."},{"key":"3031_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12185-018-2503-6","volume":"108","author":"H Sano","year":"2018","unstructured":"Sano H, Kobayashi R, Suzuki D, Kishimoto K, Hori D, Matsushima S, et al. Differential efficacy of empirical antibiotic therapy for febrile neutropenia in adolescent\/young adult (AYA) and child patients. Int J Hematol. 2018;108:543\u20139.","journal-title":"Int J Hematol"},{"key":"3031_CR16","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038\u201351.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03031-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-020-03031-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03031-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T15:28:37Z","timestamp":1614094117000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-020-03031-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["3031"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-03031-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]},"assertion":[{"value":"6 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that there are no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}